KYRNF (Kyorin Pharmaceutical Co) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KYRNF Kyorin Pharmaceutical Co Ltd KYRNF
69 GF Score
Price $10.31
GF Value $14.91
! 7 Warning Signs
View Full Analysis

What is Kyorin Pharmaceutical Co Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Kyorin Pharmaceutical Co  (OTCPK:KYRNF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Kyorin Pharmaceutical Co Cyclically Adjusted PB Ratio Related Terms


Kyorin Pharmaceutical Co Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Kyorin Pharmaceutical Co's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyorin Pharmaceutical Co Cyclically Adjusted PB Ratio Chart

Kyorin Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.96 0.94 0.94 0.52 0.52

Kyorin Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.53 0.52 0.52 0.52

KYRNF vs ZTS: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyorin Pharmaceutical Co Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Kyorin Pharmaceutical Co's Cyclically Adjusted PB Ratio falls into.


KYRNF
69GF Score
Kyorin Pharmaceutical Co Ltd KYRNF
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyorin Pharmaceutical Co Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Kyorin Pharmaceutical Co's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Kyorin Pharmaceutical Co's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=15.028/113.6000*113.6000
=15.028

Current CPI (Jun. 2026) = 113.6000.

Kyorin Pharmaceutical Co Quarterly Data

Book Value per Share CPI Adj_Book
201609 20.675 98.000 23.966
201612 18.083 98.400 20.876
201703 19.266 98.100 22.310
201706 19.173 98.500 22.112
201709 19.002 98.800 21.848
201712 19.524 99.400 22.313
201803 20.819 99.200 23.841
201806 19.667 99.200 22.522
201809 19.622 99.900 22.313
201812 19.290 99.700 21.979
201903 19.461 99.700 22.174
201906 19.511 99.800 22.209
201909 19.304 100.100 21.907
201912 19.725 100.500 22.296
202003 19.842 100.300 22.473
202006 19.896 99.900 22.624
202009 20.406 99.900 23.204
202012 20.698 99.300 23.679
202103 19.688 99.900 22.388
202106 19.038 99.500 21.736
202109 19.071 100.100 21.643
202112 18.618 100.100 21.129
202203 17.902 101.100 20.115
202206 16.059 101.800 17.920
202209 15.038 103.100 16.570
202212 16.769 104.100 18.299
202303 16.450 104.400 17.900
202306 15.062 105.200 16.265
202309 14.724 106.200 15.750
202312 15.628 106.800 16.623
202403 15.036 107.200 15.934
202406 14.073 108.200 14.775
202409 15.823 108.900 16.506
202412 14.407 110.700 14.784
202503 15.864 111.100 16.221
202506 16.408 111.700 16.687
202509 16.082 112.000 16.312
202512 15.422 113.000 15.504
202603 15.584 112.700 15.708
202606 15.028 113.600 15.028

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Kyorin Pharmaceutical Co (KYRNF) Overvalued in 2026?

Based on GuruFocus' analysis, Kyorin Pharmaceutical Co stock appears to be undervalued. The current stock price of $10.31 is trading 30.9% below its estimated GF Value™ of $14.91.

Key valuation signals for KYRNF:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $14.91 vs. price of $10.31 (30.9% below fair value)
  • GF Score™: 69/100 with 7 warning signs

No single metric tells the full story. See the KYRNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kyorin Pharmaceutical Co Business Description

Other Exchanges 4569:Japan
Address 6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
69GF Score

Get the complete analysis for KYRNF

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.31
Price
$14.91
GF Value